LIXTE Announces An Expansion Of Its Collaboration With The University Of Texas MD Anderson Cancer Center And Pharmaceutical Manufacturer GSK On An Ongoing Clinical Trial Evaluating Its Proprietary Compound LB-100 In Combination With GSK's Dostarlimab For The Treatment Of Ovarian Clear Cell Cancer

LIXTE Biotechnology Holdings (NASDAQ:LIXT) announced an expansion of its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial evaluating its proprietary compound LB-100 in combination with GSK's Dostarlimab for the treatment of ovarian clear cell cancer. The trial, initiated in January 2024 and led by Amir Jazaeri, MD, at MD Anderson, has added a second site at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University under the direction of Emily M. Hinchcliff, MD, MPH, and is expected to double enrollment to 42 patients following completion of its initial 21-patient target. The company also expects data from the initial cohort to be presented in the first half of 2026.